JP7110203B2 - 腫瘍溶解性ウイルスおよび治療用分子 - Google Patents

腫瘍溶解性ウイルスおよび治療用分子 Download PDF

Info

Publication number
JP7110203B2
JP7110203B2 JP2019535298A JP2019535298A JP7110203B2 JP 7110203 B2 JP7110203 B2 JP 7110203B2 JP 2019535298 A JP2019535298 A JP 2019535298A JP 2019535298 A JP2019535298 A JP 2019535298A JP 7110203 B2 JP7110203 B2 JP 7110203B2
Authority
JP
Japan
Prior art keywords
virus
oncolytic virus
oncolytic
cancer
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019535298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020503040A (ja
JP2020503040A5 (enExample
Inventor
フィリップ、エルブ
ジョアン、フォロップ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA filed Critical Transgene SA
Publication of JP2020503040A publication Critical patent/JP2020503040A/ja
Publication of JP2020503040A5 publication Critical patent/JP2020503040A5/ja
Application granted granted Critical
Publication of JP7110203B2 publication Critical patent/JP7110203B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04005—Cytidine deaminase (3.5.4.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C12N2710/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019535298A 2016-12-28 2017-12-21 腫瘍溶解性ウイルスおよび治療用分子 Active JP7110203B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16306831 2016-12-28
EP16306831.5 2016-12-28
PCT/EP2017/084022 WO2018122088A1 (en) 2016-12-28 2017-12-21 Oncolytic viruses and therapeutic molecules

Publications (3)

Publication Number Publication Date
JP2020503040A JP2020503040A (ja) 2020-01-30
JP2020503040A5 JP2020503040A5 (enExample) 2021-03-25
JP7110203B2 true JP7110203B2 (ja) 2022-08-01

Family

ID=57794099

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019535298A Active JP7110203B2 (ja) 2016-12-28 2017-12-21 腫瘍溶解性ウイルスおよび治療用分子

Country Status (11)

Country Link
US (1) US20190330655A1 (enExample)
EP (1) EP3562946B1 (enExample)
JP (1) JP7110203B2 (enExample)
KR (1) KR20190097240A (enExample)
CN (1) CN110168092A (enExample)
AU (1) AU2017387549B2 (enExample)
CA (1) CA3045228C (enExample)
DK (1) DK3562946T3 (enExample)
ES (1) ES2905478T3 (enExample)
IL (1) IL267639A (enExample)
WO (1) WO2018122088A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102267837B1 (ko) * 2018-01-19 2021-06-22 코오롱생명과학 주식회사 재조합 백시니아 바이러스 및 이를 포함하는 약학 조성물
SG11202106898VA (en) * 2018-12-28 2021-07-29 Transgene Sa M2-defective poxvirus
CN110747174A (zh) * 2019-10-30 2020-02-04 青岛宁逸生物科技有限公司 一种用于肿瘤治疗的重组病毒
AU2021220188A1 (en) * 2020-02-11 2022-09-08 Cytonus Therapeutics, Inc. Rapid vaccine platform
WO2021211902A2 (en) * 2020-04-15 2021-10-21 Humane Genomics Artificial oncolytic viruses and related methods
CN116421734A (zh) * 2021-12-30 2023-07-14 深圳复诺健生物科技有限公司 适用于溶瘤病毒的冻干保护剂及其应用
CN115820721B (zh) * 2022-07-26 2024-03-22 贵州大学 提高贵州优质特色稻大白果糯分蘖和产量的方法和一种启动子核心序列及应用
CN120380015A (zh) 2022-08-18 2025-07-25 特兰斯吉恩公司 嵌合痘病毒
CN119015298B (zh) * 2024-06-14 2025-07-11 贵州医科大学 表观修饰核苷在治疗肿瘤中的应用
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532053A (ja) 2006-04-07 2009-09-10 セルセントリック・リミテッド インヴィヴォでの核酸配列のエピジェネティック修飾用組成物および方法
JP2011504104A (ja) 2007-11-19 2011-02-03 トランジェーヌ、ソシエテ、アノニム ポックスウイルス腫瘍細胞崩壊性ベクター
JP2013514779A (ja) 2009-12-18 2013-05-02 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 脱メチル化および細胞の再プログラミングを促進するためのシチジンデアミナーゼ関連薬剤の使用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US6222020B1 (en) 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
CA2261989C (en) 1996-07-25 2008-09-30 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
EP1012276A2 (en) 1997-02-24 2000-06-28 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
WO1998056415A1 (en) 1997-06-11 1998-12-17 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
CA2799545A1 (en) 2000-03-07 2001-09-13 Merck Sharp & Dohme Corp. Adenovirus formulations
NZ533302A (en) 2001-12-10 2005-11-25 Bavarian Nordic As Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions containing a disaaccharide and a pharmaceutically acceptable polymer i.e. dextran or polyvinylpyrrolidon (PVP)
US20040009951A1 (en) * 2002-06-13 2004-01-15 Malim Michael H DNA deamination mediates innate immunity to (retro)viral infection
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
BRPI0618850A2 (pt) 2005-11-21 2011-09-13 Sanofi Pasteur Ltd formulações de estabilização para vìrus recombinantes
ES2611975T3 (es) 2006-06-20 2017-05-11 Transgene S.A. Procedimiento para producir poxvirus y composiciones de poxvirus
EP2029169A2 (en) 2006-06-20 2009-03-04 Transgene S.A. Recombinant viral vaccine
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
CA2676149C (en) 2007-05-14 2016-06-21 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
WO2008156655A2 (en) * 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
KR101039235B1 (ko) * 2007-08-29 2011-06-07 메디포스트(주) 제대혈 유래 간엽줄기세포를 포함하는 인터루킨-8 또는지알오-알파 발현 세포가 관련된 질병의 진단, 예방 또는치료용 조성물
AU2008328258B2 (en) 2007-11-19 2013-09-26 Transgene Sa Poxviral oncolytic vectors
CN102257134B (zh) 2008-02-12 2014-03-05 赛诺菲巴斯德有限公司 使用离子交换和凝胶过滤色谱进行痘病毒纯化的方法
JP2012509678A (ja) 2008-11-27 2012-04-26 バヴァリアン・ノルディック・アクティーゼルスカブ 組換えウイルス発現のためのプロモーター
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
JP5684787B2 (ja) 2009-04-06 2015-03-18 大塚製薬株式会社 シチジンベースの抗新生物薬とシチジンデアミナーゼ阻害薬との組合せ、および癌の治療におけるその使用
ES2628580T3 (es) 2009-04-06 2017-08-03 Otsuka Pharmaceutical Co., Ltd. Combinación de decitabina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer el tratamiento de cáncer
KR20120026526A (ko) 2009-05-12 2012-03-19 트랜스진 에스.에이. 불멸화 조류 세포주 및 그의 용도
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
WO2013022764A1 (en) 2011-08-05 2013-02-14 David Kirn Methods and compositions for production of vaccina virus
FI20115914L (fi) * 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
BR112015009320A2 (pt) 2012-10-28 2017-10-17 Bavarian Nordic As promotor pr13.5 para respostas de células t e anticorpo robustas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532053A (ja) 2006-04-07 2009-09-10 セルセントリック・リミテッド インヴィヴォでの核酸配列のエピジェネティック修飾用組成物および方法
JP2011504104A (ja) 2007-11-19 2011-02-03 トランジェーヌ、ソシエテ、アノニム ポックスウイルス腫瘍細胞崩壊性ベクター
JP2013514779A (ja) 2009-12-18 2013-05-02 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 脱メチル化および細胞の再プログラミングを促進するためのシチジンデアミナーゼ関連薬剤の使用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Chen S et al.，APOBEC3A possesses anticancer and antiviral effects by differential inhibition of HPV E6 and E7 expression on cervical cancer，Int J Clin Exp Med，2015年，Vol. 8(7)，pp. 10548-10557
Fend L et al.，Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor，OncoImmunology，2016年02月26日，Vol. 5（2）：e1080414，pp. 1-11
P32320 (CDD_HUMAN)，UniProtKB[online]，1996年，URL: https://www.uniprot.org/uniprot/P32320#sequences，[retrieved on 10.12.2021]
Q06549 (CDD_YEAST)，UniProtKB[online]，1996年，URL: https://www.uniprot.org/uniprot/Q06549，[retrieved on 10.12.2021]
Wu P F et al.，APOBEC3B: a potential factor suppressing growth of human hepatocellular carcinoma cells，Anticancer Res，2015年，Vol. 35(3)，pp. 1521-1528
Xu Y et al.，Effect of apolipoprotein B mRNA-editing catalytic polypeptide-like protein-3G in cervical cancer，Int. J. Clin. Exp. Pathol.，2015年，Vol. 8(10)，pp. 12307-12312

Also Published As

Publication number Publication date
JP2020503040A (ja) 2020-01-30
CA3045228C (en) 2024-01-02
US20190330655A1 (en) 2019-10-31
CA3045228A1 (en) 2018-07-05
WO2018122088A1 (en) 2018-07-05
EP3562946A1 (en) 2019-11-06
DK3562946T3 (da) 2022-01-31
CN110168092A (zh) 2019-08-23
IL267639A (en) 2019-08-29
AU2017387549A1 (en) 2019-07-04
EP3562946B1 (en) 2021-11-24
ES2905478T3 (es) 2022-04-08
KR20190097240A (ko) 2019-08-20
AU2017387549B2 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
JP7110203B2 (ja) 腫瘍溶解性ウイルスおよび治療用分子
JP5710261B2 (ja) ポックスウイルス腫瘍細胞崩壊性ベクター
JP5710262B2 (ja) ポックスウイルス腫瘍細胞崩壊性ベクター
Irwin et al. Targeting nucleotide biosynthesis: a strategy for improving the oncolytic potential of DNA viruses
WO2018091680A1 (en) Cowpox-based oncolytic vectors
CN112512560A (zh) 副痘病毒属载体
WO2019020543A1 (en) ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
US20260049291A1 (en) Chimeric poxviruses
JP6657115B2 (ja) ポックスウイルス腫瘍細胞崩壊性ベクター
US9687515B2 (en) Poxviral oncolytic vectors
HK40012869A (en) Oncolytic viruses and therapeutic molecules
Frendéus et al. Vector-based Cancer Immunotherapy
HK40047592A (en) Parapoxvirus vectors
HK1230971B (en) Poxviral oncolytic vectors
HK1230971A1 (en) Poxviral oncolytic vectors
HK1141541B (en) Poxviral oncolytic vectors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210215

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220624

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220720

R150 Certificate of patent or registration of utility model

Ref document number: 7110203

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150